The vials containing an expensive, controversial drug for Alzheimer's disease are fixed in size, yet the amount required by patients varies widely. This issue alone could waste $605 million in ...

Aduhelm is used to treat early stages of Alzheimer's disease. Find out what the recommended dosages are, how the drug is given, and more.

Biogen based Aduhelm’s $56,000 annual list price on the three vials required to treat a patient who weighs 163 pounds, according to The Wall Street Journal.

Aduhelm (aducanumab) is an Alzheimer's drug targeting amyloid-beta plaques in the brain to slow disease progression. It was approved amid controversy.

In Aduhelm's case, Bach says the waste could total $2 billion in annual revenues on unused drug left in vials. That's based on an assumption that the treatment will reach 500,000 patients per year ...

Biogen to cease production of controversial Alzheimer's drug The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer's disease treatment.

FDA approves new treatment for Alzheimer’s disease BioGen’s “Aduhelm” is a monthly injection intended to slow cognitive decline in patients with early stages of the disease. The FDA ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

In 2016, my colleagues and I tabulated $2 billion in excess spending across the US health care system resulting from pharmaceutical companies packaging their cancer drugs in single-dose vials that ...

The accelerated approval of a new drug intended to combat Alzheimer’s has generated concern regarding the drugs true efficacy, safety and high costs.

The Food and Drug Administration has granted accelerated approval to Aduhelm (aducanumab-avwa) for the treatment of Alzheimer disease.

STAT identified another 15 major, university-affiliated hospitals that aren’t offering the controversial new Alzheimer's drug Aduhelm.